Set Evaluation Exit Criteria When Labs Have Competing Priorities

When a Research Account Executive runs an evaluation across several labs, the real test is not the final demonstration. It is the meeting where someone has to say the evaluation is done and a decision has been made. If nobody agreed in advance on what would settle that question, the meeting turns into an argument about whose lab matters more, and the account executive gets stuck refereeing a fight that was never supposed to be theirs.

Why this conversation goes wrong

Each lab in a shared evaluation is testing the product against its own workflow, its own data, and its own definition of success. A genomics lab might care about throughput. A quality lab might care about traceability and audit trails. A discovery lab might care about how fast a researcher can get from raw data to a usable result. None of these priorities are wrong, but none of them automatically outrank the others, and nobody assigned that job to anyone.

The account executive often assumes that once every lab has run its trial and attended the demonstrations, the group is ready to decide. That assumption is usually false. Attendance is not agreement. A scientist can sit through three months of testing and still walk into the closing meeting believing their concern was never addressed, because nobody wrote down what would count as addressed. When that happens, the deal stalls, not because the product failed, but because the evaluation never had an exit.

This is a planning failure, not a persuasion failure. The fix is not a better pitch at the end. It is a clear agreement at the start about who decides, what evidence they will use, and when the decision gets made.

How to prepare

Before the evaluation starts, ask each participating lab to state the one or two things it needs to see proven. Write these down in the lab's own words. Do not let a single champion summarize for the group. If you skip this step, you will find out about a missing requirement at the worst possible time, usually in the final review.

Next, ask the group who resolves a conflict if two labs weigh their requirements differently. This person or committee should exist before the trials begin, not get appointed during a tense meeting in week ten. In most biotechnology organizations this falls to a research director, a lab head, or a small steering committee, but you cannot assume which one until someone tells you.

Map the procurement and technical review steps onto the same calendar as the lab trials. Evaluation timelines and purchasing timelines rarely move at the same speed, and a lab can finish its testing weeks before legal or IT security clears the vendor. If you have not already worked through how to align these two clocks, the post on how to Align an Evaluation Timeline With Institutional Procurement Gates walks through that separately, and it is worth doing before you set exit criteria, not after.

Finally, decide what evidence will count. A requirement without an evidence source is just an opinion. If traceability matters to one lab, name the report or audit log that will demonstrate it, and name who reviews that report.

What to say

The best moment to raise this is early, in a kickoff meeting with representatives from each lab present, not in a side conversation with your champion.

One scientist says, "Speed is what my group cares about. If it slows down our pipeline, we are out." Another scientist responds, "That is not our issue at all. Traceability is what will make or break this for us." Left alone, this exchange turns into a standoff where each lab assumes its concern should decide the outcome.

You step in and say, "Both concerns belong in the plan, and neither one has to beat the other. What I want to know is who decides how they get weighed against each other when we reach the final review, and what evidence that person needs to see." This reframes the conversation from a competition between labs into a question about process, which is a much easier question for a group to answer.

The research director, who has stayed quiet until now, says, "I will chair the final review. Have each lab send me a short statement of what it needs, and I will bring those into one document before we meet." You respond, "Good. I will build a simple tracking grid for each requirement, with the evidence source and a target date attached to it, so nobody in the final meeting is guessing what was already agreed."

Notice what you did not do in that exchange. You did not tell the speed focused scientist that traceability matters more, and you did not tell the traceability focused scientist that speed matters more. You did not try to rank the labs. You asked the group to name its own decision process, and you wrote down what came out of it.

Mistakes to avoid

A few habits sink this conversation more often than anything a lab representative says.

1. Treating your champion's opinion as the whole group's opinion. A champion in one lab cannot speak for a lab that has not been in the room. If you build your exit plan around one voice, you will find out about the gap when someone else objects at the final review.

2. Letting the evaluation run without a decision date. An evaluation with no end date can run indefinitely, and it usually does, because nobody feels pressure to converge. Set the date at the start, not once trials are already underway.

3. Trying to resolve the trade off between competing priorities yourself. That is not your decision to make, and trying to make it will cost you credibility with whichever lab you did not favor. Your job is to make the trade off visible and hand the decision to the person the customer names.

4. Assuming procurement will move on its own timeline once the labs agree. It will not. Build the procurement and technical review steps into the same schedule from day one.

How to practice and score it

This conversation is easier to run well the second time than the first, which is exactly why it is worth rehearsing before you are in front of a room full of scientists with different agendas. Practice the moment where two labs state conflicting priorities at the same time, and practice your response of naming a decision owner rather than picking a side.

Build a tracking grid with four columns, requirement, evidence source, reviewer, and decision date. Fill in a row for each lab's stated requirement. Have a manager or a peer review the grid and challenge any row that has no reviewer assigned or no date attached. A row without an owner is not a plan, it is a hope, and it will surface as a problem in the final meeting.

DealSpeak lets you rehearse this exact scenario against an AI counterpart that plays two labs with conflicting priorities, so you can practice the reframe before you need it in a real meeting. A manager can score whether you named a decision owner within the first few exchanges, whether you avoided ranking the labs yourself, and whether you left the meeting with a grid instead of a vague sense of goodwill. If you want more scenarios built around this kind of multi lab planning, the Biotechnology practice conversations hub has a full set to work through.

Closing the loop

An evaluation ends cleanly when the customer, not the vendor, has agreed on how it will end. Your job is to surface the requirements, name the decision owner, and put dates on the calendar, then let the customer's own process do the deciding. Get that structure in place early, and the closing meeting becomes a formality instead of a negotiation.